文献速递炎症性肠病

依曲莫德治疗溃疡性结肠炎的疗效:基于基线内镜严重程度对ELEVATE UC 52和ELEVATE UC 12的分析

Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-04

本文为ELEVATE UC 52和ELEVATE UC 12的事后分析,评估依曲莫德2 mg与安慰剂相比,按基线Mayo内镜评分分层的中度与重度内镜活动性溃疡性结肠炎患者的诱导和维持疗效。结果显示,在中度和重度内镜疾病亚组中,依曲莫德在临床缓解等终点上均显著优于安慰剂。

要点

  • 在中度内镜疾病亚组,依曲莫德组第12周临床缓解率38.3% vs 安慰剂组17.9%(P < .001)。
  • 在中度内镜疾病亚组,依曲莫德组第52周临床缓解率36.5% vs 安慰剂组14.3%(P < .001)。
  • 在重度内镜疾病亚组,依曲莫德组第12周临床缓解率18.2% vs 安慰剂组6.1%(P < .001)。

核心结论

  • 依曲莫德在中度和重度内镜活动性溃疡性结肠炎患者中,与安慰剂相比均显示出显著的诱导和维持疗效。
  • 重度内镜疾病患者对依曲莫德的应答可能在12周诱导治疗之后继续改善。

研究设计与样本

  • ELEVATE UC 52和ELEVATE UC 12的事后分析,评估依曲莫德2 mg与安慰剂按基线Mayo内镜评分分层的诱导和维持疗效。
  • 中度与重度内镜疾病分别定义为集中判读的内镜评分为2分和3分。
  • 疗效终点在第12周(汇总人群)和第52周(ELEVATE UC 52)评估。
  • 亚组分析按基线改良Mayo评分(4-6 vs 7-9)和既往生物制剂/Janus激酶抑制剂暴露分层。
  • 接受依曲莫德治疗的中度内镜疾病患者235例、重度内镜疾病患者292例;接受安慰剂的中度内镜疾病患者112例、重度内镜疾病患者148例。

主要发现

  • 中度内镜疾病亚组:依曲莫德组第12周临床缓解率38.3% vs 安慰剂组17.9%,第52周36.5% vs 14.3%(均P < .001)。
  • 重度内镜疾病亚组:依曲莫德组第12周临床缓解率18.2% vs 安慰剂组6.1%,第52周29.4% vs 3.4%(均P < .001)。
  • 大多数终点在第12周和第52周观察到相似疗效。
  • 重度内镜疾病患者中,依曲莫德组达到终点的比例在第52周通常数值上高于第12周(相对于安慰剂)。
  • 亚组分析结果总体相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis. In this post hoc analysis, induction and maintenance efficacy of etrasimod 2 mg versus placebo were assessed by baseline Mayo endoscopic subscore in ELEVATE UC 52 and ELEVATE UC 12. METHODS: Moderate and severe endoscopic disease were defined as a centrally read endoscopic subscore of 2 and 3, respectively. Efficacy end points were evaluated at Weeks 12 (pooled population) and 52 (ELEVATE UC 52). Subgroup analyses were stratified by baseline modified Mayo score (4-6 vs 7-9) and prior biologic/Janus kinase inhibitor exposure. RESULTS: Overall, 235 patients with moderate and 292 with severe endoscopic disease received etrasimod; 112 and 148 patients, respectively, received placebo. At both time points, significantly greater proportions of patients receiving etrasimod compared with placebo achieved clinical remission in the moderate (Week 12: 38.3% vs 17.9%; Week 52: 36.5% vs 14.3%; both P < .001) and severe (Week 12: 18.2% vs 6.1%; Week 52: 29.4% vs 3.4%; both P < .001) endoscopic disease subgroups. Similar efficacy was observed at Weeks 12 and 52 for most end points. The proportion of etrasimod-treated patients with severe endoscopic disease achieving end points was generally numerically higher at Week 52 versus Week 12, relative to placebo. Subgroup analysis findings were generally similar. CONCLUSIONS: Etrasimod demonstrated significant induction and maintenance efficacy over placebo in both moderate and severe endoscopic disease. Response to etrasimod in patients with severe endoscopic disease may continue to improve beyond 12-week induction therapy (ClinicalTrials.gov: NCT03945188; NCT03996369).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Yarur AJ, Reinisch W, Chang S, et al. Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity. Clin Gastroenterol Hepatol. 2025. PMID: 40618942. doi:10.1016/j.cgh.2025.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。